Partnerships TheraCour Pharma, Inc. (related party): platform IP licenses; 15% net-sales royalty; development activities performed by TheraCour; KMPL (India) sponsored the Phase Ia/Ib trial
Indications
COVID-19(Phase 1)
MPox(Phase 1)
Smallpox(Phase 1)
Measles(Phase 1)
RSV(Phase 1)
Status note Broad-spectrum antiviral nanoviricide. Phase Ia/Ib safety/tolerability trial of NV-CoV-2 oral formulations (API NV-387) in healthy subjects completed (KMPL-sponsored, India); final CSR pending. Phase II planned (MPox first); FDA Orphan Drug Designation granted for measles treatment Apr 27, 2026; pre-IND engagements planned for MPox, Smallpox, Measles and RSV.
Partnerships TheraCour Pharma, Inc. (related party): platform IP licenses; 15% net-sales royalty
Indications
Shingles (VZV)(Preclinical)
HSV-1 cold sores(Preclinical)
HSV-2 genital ulcers(Preclinical)
Status note Preclinical. IND-enabling safety-pharmacology studies completed for the Shingles skin-cream formulation toward a US IND filing; systemic formulation also in development.
NV-HIV-1
Preclinical · ActiveModality: nanoviricide
Target HIV
Partnerships TheraCour Pharma, Inc. (related party): platform IP licenses; 15% net-sales royalty
Indications
HIV(Preclinical)
Status note Preclinical; company states activity in an HIV mouse model warrants further regulatory development.
Partnerships KMPL (India): out-license for clinical development and commercialization in India
Indications
COVID-19(Preclinical)
Status note Second COVID-19 clinical-test candidate out-licensed to KMPL; no clinical trial disclosed.
Per-asset detail extracted from the 10-Q filed 2026-05-15. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.